Key Points {#FPar1}
==========

Quizartinib is a tyrosine kinase inhibitor that selectively targets *FLT3*-ITD mutations in patients with acute myeloid leukaemia, so it is worthwhile retesting mutation status at each relapse to identify patients who become candidates for quizartinib after converting from *FLT3*-*ITD* mutation-negative to -positive during chemotherapyThere is a potential for QTcF prolongation during quizartinib treatment, but this is almost invariably asymptomatic and reversible, and can be easily managed by dose reductionQuizartinib is metabolised by cytochrome P450 3A4 enzymes, so careful attention should be paid to the choice of concomitant medications, including antifungal prophylaxis, to avoid drug--drug interactions

Introduction {#Sec1}
============

Acute myeloid leukaemia (AML) is an aggressive clonal haematological malignancy in which the haematopoietic process for myeloid cells is altered, resulting in differentiation arrest of myeloid progenitor cells and the proliferation of undifferentiated or poorly differentiated blood cells in bone marrow and blood \[[@CR1], [@CR2]\].

Approximately 30% of patients with AML have a mutation in the gene for FMS-like tyrosine kinase 3 (*FLT3*) \[[@CR3]\], which may be an internal tandem duplication (ITD) mutation (the most common form) or a point mutation in the tyrosine kinase domain (TKD) \[[@CR4]\]. The presence of an *FLT3*-ITD mutation is prognostic of a poor outcome in terms of survival and risk of relapse \[[@CR5]--[@CR10]\], and partially counteracts the normally favourable prognostic benefit of having a nucleophosmin (*NPM1*) gene mutation \[[@CR6], [@CR7]\]. For example, studies showed a significantly shorter median duration of overall survival (OS) in patients with mutant *FLT3*-ITD compared with wild-type *FLT3* (13.8 vs 22 months, respectively) \[[@CR8]\], and that the 3-year OS rate in these two groups was 14 and 22--23%, respectively \[[@CR7], [@CR10]\].

The tyrosine kinase inhibitor quizartinib (AC220; Daiichi Sankyo) is highly selective for FLT3, with up to tenfold higher affinity for FLT3 than for other receptor tyrosine kinases \[[@CR11]\]. In Phase 1 and 2 studies, once-daily quizartinib showed antitumour activity in patients with relapsed/refractory AML and *FLT3*-ITD mutations and had an acceptable toxicity profile \[[@CR12], [@CR13]\]. The dose-limiting toxicity was QT interval prolongation on electrocardiogram (ECG), using the QT interval corrected according to the Fridericia formula (QTcF).

The efficacy and safety of quizartinib, which has recently been approved in Japan \[[@CR14]\], have been evaluated in the Phase 3 QuANTUM-R study, which showed that quizartinib monotherapy improved OS compared with salvage chemotherapy in patients with relapsed/refractory *FLT3*-ITD mutation-positive AML \[[@CR15]\]. During the course of the QuANTUM-R study, patients were enrolled whose clinical course provided interesting observations about treatment issues specific to quizartinib. The current article provides commentary on four patients who participated in QuANTUM-R, and whose condition and/or clinical course illustrates issues specific to the use of quizartinib.

Changes in Mutational Status {#Sec2}
============================

The genomic architecture of AML evolves through the course of the disease, as chemotherapy and disease progression affect blast characteristics \[[@CR16]--[@CR19]\]. Relapse is often caused by the emergence of chemo-resistant clones after treatment \[[@CR20]\]. However, because mutations like *FLT3* are now targets for novel chemotherapeutic agents, it is worthwhile retesting a patient's molecular biology at relapse to identify the emergence of novel mutations that may be sensitive to targeted therapies. The following case description involves a patient who was *FLT3*-ITD-negative at diagnosis but was later found to be *FLT3*-ITD-positive after five regimens of unsuccessful treatment, including haematopoietic stem cell transplantation (HSCT).

Illustrative Case {#Sec3}
-----------------

A previously healthy 46-year-old male with no medical history of interest was diagnosed with AML after presenting with skin lesions, anaemia (haemoglobin 10.3 g/dL), thrombocytopenia (platelets 35 × 10^9^ cells/L), and leucocytosis (white blood cells 19.5 × 10^9^ cells/L; 20% blasts in peripheral blood). Bone marrow assessment showed 15% blast cells and evidence of fibrosis. Cytogenetics were 46,XY\[21\], and the patient's mutational analysis was positive for *NPM1* and negative for *FLT3*-ITD.

The patient received induction therapy according to the PETHEMA LMA 2010 \< 65 regimen (idarubicin 12 mg/m^2^/day on Days 1--3 of the cycle and cytarabine 200 mg/m^2^/day on Days 1--7) \[[@CR21]\], but did not respond. The patient then underwent three regimens of salvage chemotherapy (high-dose cytarabine, FLAG-Ida \[fludarabine, cytarabine, and granulocyte-colony stimulating factor with idarubicin\] \[[@CR21]\], and a clinical trial with intensive treatment) without response. The final salvage treatment attempted was sequential HSCT, which achieved a complete response.

Two months after the HSCT, the patient relapsed and met the criteria to be enrolled in the QuANTUM-R study, with an *FLT3*-ITD mutation (ratio 0.06), and a normal ECG (mean QTcF 407 ms). He was randomised to quizartinib with a starting dose of 30 mg/day in cycle 1. This dose was well tolerated, with no ECG changes, so the quizartinib dose was increased to 60 mg/day as planned in the study protocol.

Cycle 2 evaluations showed a continuing response, with 2% blast cells in bone marrow and haematologic recovery. On Day 1 of cycle 5, the patient had reported a submandibular growth. Unlike a computed tomography (CT) scan of the head and neck (Fig. [1](#Fig1){ref-type="fig"}), where the tumour appeared to be left submaxillitis and reactive lymphadenopathy, subsequent biopsy showed that it was a granulocytic sarcoma. As the patient had no evidence of bone marrow infiltration (no blast cells with complete donor chimerism in the subsequent assessment) and had already undergone numerous salvage treatments, continuation of quizartinib with the addition of radiotherapy to treat extramedullary disease was considered the best treatment option.Fig. 1Axial CT scan at the C1 level showing submaxillary swelling and lymphadenopathy on the left side

Afterwards, bone marrow evaluations showed persistent complete response, but at the end of cycle 9, the patient developed abdominal pain, hyperbilirubinaemia and renal impairment, with CT evidence of tumoural infiltration of the gall bladder and extrahepatic bile ducts, and bilateral involvement of the kidneys and ureters (Fig. [2](#Fig2){ref-type="fig"}a, b). The patient also had a thrombosis in the horizontal segment of the left portal vein, and a partial thrombosis in the right portal branch for the anterior segments. At this time, the patient's bone marrow contained 7% blast cells. Quizartinib treatment was stopped and the patient withdrew from the study. Despite an initial response to two cycles of non-intensive chemotherapy after trial withdrawal, new extra medullary relapse occurred and the patient died 14 months after the last study visit.Fig. 2Coronal (**a**) and axial (**b**) CT scans of the abdomen showing extramedullary disease with ureteral involvement after cycle 9 of quizartinib

Discussion {#Sec4}
----------

This case illustrates that mutational status can change during the course of AML, particularly in treated patients, such that a patient who initially presents as *FLT3*-ITD negative may become *FLT3*-ITD positive.

There may be a number of reasons why a patient presents with a negative *FLT3*-ITD status and later becomes *FLT3*-ITD positive, including AML blasts gaining this mutation during the course of treatment. Such shifts in *FLT3* status have been reported previously by numerous researchers \[[@CR22]--[@CR27]\] and are more common than changes in *NMP1* status between diagnosis and relapse. Among the changes in *FLT3* mutations reported during the course of AML treatment, the gain of ITD is more common than the loss of TKDs \[[@CR24]\].

The possibility of an undetected *FLT3* mutation at diagnosis in this case is unlikely since modern high-sensitivity PCR assays are able to detect *FLT3* mutations when such mutations are present in ≤ 1% of cells \[[@CR12], [@CR28]\].

Managing ECG Changes {#Sec5}
====================

Quizartinib is associated with QTcF prolongation \[[@CR13]\], which is a marker for potentially serious cardiac arrhythmias such as torsade de pointes \[[@CR29]\] and requires careful management. In the Phase 1 quizartinib study, 5% of patients developed grade 3 QTc prolongation \[[@CR13]\], which affected the protocols for the subsequent Phase 2 and 3 studies, including QuANTUM-R \[[@CR12], [@CR30]\]. The QuANTUM-R study used a lower dose of quizartinib (60 mg/day) than had been used in the Phase 1 (maximum tolerated dose 200 mg/day) and Phase 2 (135 mg/day for men and 90 mg/day for women in the majority of patients) studies \[[@CR15]\]. It was hypothesised that a 60 mg/day dose of quizartinib would be as effective as the higher doses, but would be associated with a lower risk of heart rate abnormalities.

The case report below describes a patient in the QuANTUM-R study who developed grade 2 QTcF prolongation (QTcF \> 480 ms) but was able to continue quizartinib treatment at a reduced dose and subsequently achieved a complete remission.

Illustrative Case {#Sec6}
-----------------

A previously healthy 34-year-old male with no medical history of interest was diagnosed with AML after presenting with anaemia (haemoglobin 7.9 g/dL), leukopenia (white blood cells 0.83 × 10^9^ cells/L; 1% blast cells) and thrombocytopenia (64 × 10^9^ cells/L). At diagnosis, his bone marrow showed 81% blast cells and his cytogenetic profile was 47,XY, + 6\[11\]/46,XY\[3\]. Mutational analysis showed that he was *NPM1* negative and *FLT3*-ITD positive (ratio 0.31).

The patient underwent 1 cycle of induction therapy with PETHEMA LMA 2010 \< 65 and achieved a complete response, but with positive minimal residual disease (MRD). Consolidation therapy using the same regimen was completed without complications. HSCT was planned, but he relapsed within 1 month of completing consolidation therapy (the bone marrow contained 34% blast cells). On assessment, this patient was eligible for the QuANTUM-R trial. At study entry, there was an *FLT3*-ITD mutation (ratio 0.58) and there were no ECG abnormalities (mean baseline QTcF interval of 384 ms) (Fig. [3](#Fig3){ref-type="fig"}a). He was transfusion dependent and was receiving ciprofloxacin and isoniazid prophylaxis (positive QuantiFeron test for tuberculosis infection at diagnosis), fluconazole, ceftibuten and levofloxacin.Fig. 3ECG from a patient (**a**) at screening, showing a normal QTcF interval (385 ms), and (**b**) during quizartinib 60 mg, when QTcF was prolonged to 488 ms, prompting a dose reduction

The patient was randomised to quizartinib and received cycle 1 treatment at 30 mg/day without adverse events (AEs) and with no pathological ECG changes excepting a heart rate of 58 beats/min; the dose of quizartinib was increased to 60 mg/day on Day 15. During cycle 4, a routine ECG showed an increase in the QTcF interval to 488 ms (Fig. [3](#Fig3){ref-type="fig"}b), requiring a reduction in the quizartinib dose to 30 mg/day (electrolytes were within normal range at this time). After cycle 4, the patient's QTcF interval normalised to 403 ms, and the quizartinib dose was increased to 60 mg/day.

Bone marrow assessment showed a complete response after cycle 5 (with partial remission reached after cycle 1 and 3). Allogeneic HSCT was performed after the cycle 6. The patient received four post-HSCT cycles of quizartinib; although he remained bradycardic, he did not experience any significant complications. Twenty-three months after the HSCT, the patient was alive and in complete remission with no evidence of MRD.

Discussion {#Sec7}
----------

This case illustrates that quizartinib treatment can be successfully continued, albeit at a reduced dose, in patients who develop grade ≤ 2 QTcF prolongation (QTcF \< 499 ms), a finding consistent with data from the Phase 1 and 2 studies \[[@CR12], [@CR13]\]. In the Phase 1 and 2 studies with quizartinib, QTcF prolongation was reversible, asymptomatic and not associated with any arrhythmias \[[@CR12], [@CR13]\], which was also true of the patient from QuANTUM-R reported here. Although potential drug-drug interactions could have contributed to the QTcF prolongation seen in this patient, pharmacokinetic studies indicate that quizartinib dose reductions are not required when coadministered with weak or moderate CYP3A4 inhibitors \[[@CR14], [@CR31]\], such as isoniazid and fluconazole, respectively. No other concomitant medications with known interactions were administered in this patient. It is encouraging to know that any QTcF prolongation that may occur with quizartinib is almost invariably asymptomatic and reversible, and can be easily managed by dose reduction.

Potential Drug--Drug Interactions {#Sec8}
=================================

Oral quizartinib is extensively metabolised in the liver by the cytochrome P450 (CYP) 3A4 enzyme, producing a major metabolite that is also active against FLT3 in vitro \[[@CR32]\]. Therefore, the antitumour activity of quizartinib may be affected by agents that are inhibitors or inducers of CYP3A4 (e.g. azole antifungal agents). In addition, in vitro data indicate that quizartinib inhibits the ATP-binding cassette (ABC) G2, also known as breast cancer resistance protein (BCRP), at pharmacologically relevant doses, which may also have pharmacokinetic implications \[[@CR33]\].

To date, little is known about the potential for quizartinib to interact with other agents used clinically in the treatment of AML. This case describes a patient who developed repeated infections during the course of her AML and required prophylaxis with multiple anti-infective agents during treatment with quizartinib. When choosing prophylactic agents, we avoided strong CYP3A4 inhibitors to minimise the potential for drug-drug interactions.

Illustrative Case {#Sec9}
-----------------

A 34-year-old woman with no significant medical history was diagnosed with AML. Cytogenetics showed a normal (46,XX) karyotype and she was negative for *NPM1*, and positive for *FLT3*-ITD mutations (ratio unknown at diagnosis).

The patient began induction treatment with the PETHEMA LMA 2010 \< 65 regimen and experienced a partial response after 2 cycles (6% blasts in bone marrow). In addition, she experienced neutropenic enterocolitis, mucositis (grade 2), and *Enterococcus faecium* bacteraemia. As salvage therapy, FLAG-Ida was administered, followed by *Clostridium difficile* colitis and bacteraemia (causative pathogens were coagulase-negative *Staphylococcus* and *Escherichia coli*) but no complete remission was obtained. Nevertheless, the patient underwent allogeneic HSCT from a 9/10 HLA-matched unrelated donor, achieving complete remission with complete chimerism according to the bone marrow assessment performed on Day 31. Unfortunately, by day 121, the patient relapsed and was selected for the QuANTUM-R study.

The patient was randomised to quizartinib and was treated with a 30 mg/day dose in cycle 1, increasing to 60 mg/day in subsequent cycles, as she met the corresponding criteria. She also received antimicrobial prophylaxis with levofloxacin, cotrimoxazole and acyclovir. Rather than initiating antifungal prophylaxis, monitoring the patient twice weekly for the presence of *Aspergillus* antigens in blood was considered the best choice.

At the end of cycle 3, the patient was hospitalised for bacteraemia, which was resolved with teicoplanin. Although the causative pathogen was coagulase-negative *Staphylococcus*, computed tomography scan of the thorax was normal and *Aspergillus* antigens in blood were consistently negative, quizartinib was stopped for 1 week and the patient received posaconazole during this time.

After cycle 4, the bone marrow assessment showed complete response, so a second allogeneic HSCT was planned. Antifungal prophylaxis with micafungin was added to her previous prophylactic regimen during conditioning, but the patient developed fever despite the broad infectious coverage. On Day 3 from HSCT, a chest x-ray showed bilateral infiltrates. Throughout treatment, the patient had returned consistently negative results for *Aspergillus* antigenaemia but bronchoalveolar lavage fluid was positive for *Aspergillus* spp. Finally, she developed respiratory failure and died due to invasive fungal infection.

Discussion {#Sec10}
----------

This complex patient experienced multiple infective complications during the course of the AML. In addition to regularly monitoring for the presence of *Aspergillus* antigens (which is an accurate marker for invasive fungal infections \[[@CR34]\]), when quizartinib was initiated, physicians considered antimicrobial agents with known little potential for drug--drug interactions \[[@CR35]\]. In fact, only when quizartinib was stopped, the patient received a strong CYP3A4 inhibitor like posaconazole. However, regular ECG monitoring and dose reduction (which is recommended when strong CYP3A4 inhibitors are co-administered \[[@CR14]\]) could have been considered a better option.

This case highlights the importance of introducing antifungal prophylaxis, while reducing the dose of quizartinib, which is preferable to avoid the use of some necessary drugs that could improve the prognostic of the disease \[[@CR36]\].

Maintenance Therapy {#Sec11}
===================

There is currently limited information about the durability of response to quizartinib or whether quizartinib can be used as maintenance therapy after HSCT. The following case describes a patient who achieved an early complete remission and was subsequently able to undergo HSCT, and then went on to receive quizartinib maintenance therapy.

Illustrative Case {#Sec12}
-----------------

A 55-year-old man with an unremarkable medical history was diagnosed with AML. At diagnosis, he had a haemoglobin level of 10.7 g/dL, white blood cell count of 1.7 × 10^9^ cells/L, 24% blasts and a platelet count of 151 × 10^9^/L. Based on his bone marrow assessment, which had a blast count of 87%, the patient's karyotype was 46,XY\[21\], and he was negative for *NPM1* mutation but positive for *FLT3*-ITD mutation (ratio 0.67).

The patient received induction therapy with the PETHEMA LMA 2010 \< 65 regimen, but did not respond. According to his clinical profile, the patient was a candidate for FLAG-Ida (fludarabine, cytarabine and idarubicin), but his mutation status also made quizartinib a treatment option. At this time, the patient was *FLT3*-ITD positive with a ratio of 0.11, had 45% bone marrow blasts, was not taking any concomitant medication, and had no pathological ECG findings (baseline QTcF interval of 374 ms).

The patient entered the QuANTUM-R study and was randomised to oral quizartinib at a starting dose of 30 mg/day, increasing the dose of quizartinib to 60 mg/day during this course. The patient did not develop fever ≥ 38 °C or any form of cytopenia.

After the first cycle of quizartinib, the patient's bone marrow aspirate contained 3% blasts, and his blood count parameters had improved from baseline (haemoglobin 13.5 g/dL, platelets 337 × 10^9^/L, and white blood cells 3.3 × 10^9^ cells/L, including neutrophils 2.1 × 10^9^ cells/L). Complete remission was maintained and quizartinib was discontinued after 7 days of cycle 4 to initiate the HSCT preparation protocol. A myeloablative haploidentical HSCT was performed without serious complications. The patient was receiving standard anti-infective prophylaxis and immunosuppressive therapy with posaconazole, sirolimus, cotrimoxazole, prednisone and acyclovir when a bone marrow assessment 80 days post-HSCT showed no blasts. At this time, quizartinib was restarted at an initial dose of 20 mg/day on account of the patient had also a neutrophil count \> 1 × 10^9^ cells/L and platelets \> 50 × 10^9^/L, and no evidence of acute or chronic GVHD. QTcF remained within normal limits on Day 15, so the dose of quizartinib was increased to 30 mg/day according to the study protocol. On Day 1 of cycle 3, posaconazole was withdrawn and the dose was increased again to 60 mg/day. The patient remains in remission while continuing quizartinib treatment; to date he has received 35 cycles (4 prior to and 31 since the HSCT) without complications or the need for concomitant treatment.

Discussion {#Sec13}
----------

To date, there is limited information about the long-term use of quizartinib as maintenance therapy. One small Phase 1 study evaluated quizartinib as maintenance therapy in a cohort of 13 patients who had undergone allogeneic HSCT \[[@CR37]\]. Treatment with quizartinib was continued for 24 cycles unless the patient relapsed or had persistent grade 3 or 4 toxicity \[[@CR37]\]. Three patients died during this study, but 10 patients were treated with quizartinib for more than 1 year, and six of these patients received treatment for almost 2 years \[[@CR37]\]. The overall survival ranged from 13 to 142 weeks; nine patients survived for \> 1 year and four for \> 2 years \[[@CR37]\]. No patient showed a reduction in donor chimerism during maintenance quizartinib treatment after HSCT \[[@CR37]\]. In this small study, the most common grade 3 or 4 AEs were haematological, with grade 3 or 4 leukopenia, anaemia, thrombocytopenia or lymphopenia each occurring in two patients (15%) and neutropenia developing in three (23%) \[[@CR37]\]. Six patients received granulocyte colony-stimulating factor.

In our case study, the patient did not develop any cytopenias during quizartinib treatment, before or after HSCT. These promising data suggest that quizartinib can rapidly produce complete remission in some patients with relapsed/refractory AML, consistent with the response seen in the current case study, allowing them to undergo HSCT. Moreover, quizartinib can be safely continued as long-term maintenance therapy after HSCT.

Closing Remarks {#Sec14}
===============

These cases illustrate several of the key issues to be addressed when treating patients with AML, particularly when transitioning to treatment with quizartinib.Monitoring the genomic architecture of AML during the disease course, and retesting genetic alterations at each relapse or when resistance to treatment emerges may identify mutations that are sensitive to targeted therapies, such as quizartinib.There is a potential for QTcF prolongation with quizartinib or arising out of pharmacokinetic drug-drug interactions. Careful monitoring of the ECG means that risk mitigation strategies, such as dose reductions when QTcF prolongation exceeds 480 ms or switching/discontinuing coadministered drugs, should be implemented without interrupting quizartinib treatment.In some circumstances, managing drug interactions is preferable, so that patients can be treated concomitantly with the necessary drugs, in this case azoles and quizartinib.Quizartinib can be continued as long-term maintenance therapy after HSCT until relapse or unacceptable toxicity, although the optimal duration of maintenance therapy is unknown at present.

While quizartinib appears to be an effective and well-tolerated treatment option for patients with *FLT3*-ITD relapsed/refractory AML, adequate management of these key issues remains essential for therapeutic success.
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